- Previous Close
67.39 - Open
67.83 - Bid 52.89 x 100
- Ask 86.13 x 100
- Day's Range
66.90 - 73.97 - 52 Week Range
36.61 - 73.97 - Volume
5,092,614 - Avg. Volume
867,736 - Market Cap (intraday)
3.301B - Beta (5Y Monthly) -1.69
- PE Ratio (TTM)
-- - EPS (TTM)
-4.38 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
98.38
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
soleno.lifeRecent News: SLNO
View MorePerformance Overview: SLNO
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLNO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLNO
View MoreValuation Measures
Market Cap
3.30B
Enterprise Value
3.06B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.06%
Return on Equity (ttm)
-87.35%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-175.85M
Diluted EPS (ttm)
-4.38
Balance Sheet and Cash Flow
Total Cash (mrq)
291.44M
Total Debt/Equity (mrq)
21.55%
Levered Free Cash Flow (ttm)
-7.47M